Skip to content
Review Open access

RNA 5-Methylcytosine (m5C) in Cancer: An Emerging Epitranscriptomic Hub for Therapy Resistance and Clinical Translation.

Nov 2026 · Wiley Interdisciplinary Reviews - RNA · Vol 17 6 · 0 citations · 175 references
Medicine

Abstract

RNA 5-methylcytosine (m5C) has emerged as an important epitranscriptomic modification in cancer. Rather than acting as a uniformly oncogenic mark, m5C produces context-dependent effects by coupling RNA fate to cellular adaptation. Through control of RNA stability, nuclear export, translation, splicing, and RNA structure, the m5C machinery connects therapeutic stress to DNA damage repair, redox homeostasis, metabolic plasticity, cancer stemness, and tumor-immune interactions. Here, we synthesize the molecular basis of and detection of RNA m5C, distinguish causal from associative evidence, and examine how m5C-dependent RNA regulation contributes to tumor progression and resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy responses. We also discuss tumor-suppressive and context-dependent activities of individual NSUN proteins, cross-talk with other epigenetic and epitranscriptomic pathways, and the methodological limitations that complicate m5C mapping. Current m5C-directed compounds remain preclinical; therefore, their most immediate value lies in mechanistic validation and biomarker development rather than established clinical use. A rigorous, method-aware framework will be essential for determining when m5C is a driver, a permissive adaptation, or a correlate of therapeutic resistance.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.